PharmAla Launches MDMA Clinical Trial Tool for Researchers
22 août 2024 09h07 HE
|
PharmAla Biotech
PharmAla announces the launching of a new tool for clinical researchers, and the appointment of a new CFO effective Oct. 1
atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT)
13 août 2024 07h00 HE
|
atai Life Sciences
VLS-01 demonstrated a good safety and tolerability profile and a short psychedelic experience, enabling a total in-clinic treatment of two hours.
MAPS Statement on FDA Complete Response Letter for MDMA-Assisted Therapy for PTSD New Drug Application
09 août 2024 21h33 HE
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
MAPS remains confident in its goal of making access to MDMA-assisted therapy for PTSD safe and legal SAN JOSE, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- The Multidisciplinary Association for...
PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
09 août 2024 18h18 HE
|
PharmAla Biotech
PharmAla expresses disappointment in USFDA's decision to request a third Phase 3 for MDMA and announces the patent granting for a safer MDMA analog variant
atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference
07 août 2024 07h00 HE
|
atai Life Sciences
atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference in August 2024
PharmAla Provides Comprehensive Investor Update Following Release of Q3 Financial Statement
30 juil. 2024 08h55 HE
|
PharmAla Biotech
PharmAla releases a comprehensive investor update following its Q3 financial release, including highlights such as a 10x revenue increase and patent update
Psychedelic Drug (Ketamine, Psilocybin) Research Report 2024: A Global $4.6 Billion Market by 2030 - Strategic Analysis, Trends, Forecasts and Competitive Analysis 2018-2023 & 2024-2030
24 juil. 2024 09h50 HE
|
Research and Markets
Dublin, July 24, 2024 (GLOBE NEWSWIRE) -- The "Psychedelic Drug Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.The...
Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference
12 juil. 2024 08h02 HE
|
Clearmind Medicine Inc.
Vancouver, Canada, July 12, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...
Hallucinogenics: Leading Dispensary in Canada Celebrates 1st Anniversary
09 juil. 2024 09h00 HE
|
Hallucinogenics
Ottawa, Canada, July 09, 2024 (GLOBE NEWSWIRE) -- Hallucinogenics, a premier Magic mushroom, LSD, and DMT dispensary in Canada, is excited to announce the celebration of its 1 year anniversary of...
atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
26 juin 2024 07h00 HE
|
atai Life Sciences
NEW YORK and BERLIN, June 26, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental...